The PPARs: From Orphan Receptors to Drug Discovery
The DOI matches its Crossref record; 215 of the 216 references it cites were found in a registry or an index.
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTThe PPARs: From Orphan Receptors to Drug Discovery†Timothy M. Willson, Peter J. Brown, Daniel D. Sternbach, and Brad R. HenkeView Author Information Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709 Cite this: J. Med. Chem. 2000, 43, 4, 527–550Publication Date (Web):February 24, 2000Publication History Received8 November 1999Published online24 February 2000Published inissue 1 February 2000https://pubs.acs.org/doi/10.1021/jm990554ghttps://doi.org/10.1021/jm990554greview-articleACS PublicationsCopyright © 2000 American Chemical SocietyRequest reuse permissionsArticle Views6740Altmetric-Citations1452LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Agonists,Ligands,Lipids,Receptors,Rodent models Get e-Alerts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pemafibrate is an extremely selective PPARα agonist (subtype selectivity > 5000-fold for PPARγ and > 11,000-fold for PPARδ, respectively) [49, 50].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
In the citing paper
“The PPARα activation by pemafibrate was > 2500 times stronger than fenofibric acid, the active form of fenofibrate.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
Citations
Cites
Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale
DeRisi, J. L., Iyer, V. R., & Brown, P. O. (1997) · Science · doi:10.1126/science.278.5338.680 · Cited by 4,456
Self-citationA Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis
Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M., & Spiegelman, B. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81410-5 · Cited by 3,864
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Self-citationActivation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., & Spiegelman, B. M. (1994) · Genes & Development · doi:10.1101/gad.8.10.1224 · Cited by 2,181
Research works printed but not linked: 124
- Lichtenstein A. H., 1998, Nutr. Rev., 56, S28
- Harris M. I., 1998, Diabetes Care, 21, 524
- Howard B. V., 1995, Int. Congr. Ser.
- Barzilai N., 1999, J. Gerontol., Ser. A, 54, B96
- Lichtenstein A. H., 1999, Nutr. Rev., 57, 14
- Jump D. B., 1999, Annu. Rev. Nutr., 19, 90
- Mangelsdorf D. J., 1995, Cell, 83, 850
- A, 1999, Cell, 97, 163
- Xu H. E., 1999, Mol. Cell, 3, 403
- Hu E., 1996, Science, 274, 2103
- Zhang B., 1996, J. Biol. Chem., 271, 31774
- Adams M., 1997, J. Biol. Chem., 272, 5132
- Camp H. S., 1999, Endocrinology, 140, 397
- Juge-Aubry C. E., 1999, J. Biol. Chem., 274, 10510
- McDonnell D. P., 1993, Bio/Technology, 11, 1261
- Lehmann J. M., 1995, J. Biol. Chem., 270, 12956
- Xu L., 1999, Curr. Opin. Genet. Dev., 9, 147
- Zhu Y., 1996, Gene Expression, 6, 195
- Dowell P., 1997, J. Biol. Chem., 272, 33443
- Zhu Y., 1997, J. Biol. Chem., 272, 25506
- Yuan C.-X., 1998, Proc. Natl. Acad. Sci. U.S.A., 95, 7944
- Treuter E., 1998, Mol. Endocrinol., 12, 881, 10.1210/mend.12.6.0123 · doi:10.1210/mend.12.6.0123 · Paper page
- Krey G., 1997, Mol. Endocrinol., 11, 791, 10.1210/mend.11.6.0007 · DOI · Paper page
- Zhou G., 1998, Mol. Endocrinol., 12, 1604, 10.1210/mend.12.10.0176 · doi:10.1210/mend.12.10.0176 · Paper page
- Berger J., 1996, Endocrinology, 137, 4195
- Young P. W., 1998, J. Pharmacol. Exp. Ther., 284, 759
- Bell A. R., 1998, Biochem. J., 332, 693
- Heuvel J. P. V, 1999, Toxicol. Sci., 47, 8
- Palmer C. N. A., 1998, Mol. Pharmacol., 53, 22
- Gervois P., 1999, Mol. Endocrinol., 13, 1549
- Gaw A., 1994, Handb. Exp. Pharmacol., 109, 348
- Brown P. J., 1997, Synthesis, 778, 782
- Brown P. J., 1999, J. Med. Chem., 42, 3788
- Forman B. M., 1997, Proc. Natl. Acad. Sci. U.S.A., 94, 4317
- Yu K., 1995, J. Biol. Chem., 270, 23983
- Palmer C. N. A., 1994, J. Biol. Chem., 269, 18089
- Lee S. S.-T., 1995, Mol. Cell. Biol., 15, 3022
- Peters J. M., 1997, J. Biol. Chem., 272, 27312
- Gaw A., 1999, Lipoproteins Health Dis., 1145, 1160
- Ross S. D., 1999, Arch. Intern. Med., 159, 1802
- Oliver M. F., 1984, Lancet, 2, 604
- Rutolo G., 1998, J. Am. Coll. Cardiol., 32, 1656
- Libby P., 1999, Mol. Basis Cardiovasc. Dis., 349, 366
- Spencer N. F. L., 1997, Int. Immunol., 9, 1588
- Delerive P., 1999, J. Biol. Chem., 45, 32054
- Vazquez M., 1995, Br. J. Pharmacol., 116, 2075
- Jacobsson A., 1985, J. Biol. Chem., 260, 16254
- Krook A., 1998, Diabetes, 47, 1531
- Ruyter B., 1997, Biochim. Biophys. Acta, 1348, 338
- Zhu Y., 1993, J. Biol. Chem., 268, 26820
- Greene M. E., 1995, Gene Expression, 4, 299
- Chawla A., 1994, Endocrinology, 135, 800, 10.1210/endo.135.2.8033830 · doi:10.1210/endo.135.2.8033830 · Paper page
- Saladin R., 1999, Cell Growth Differ., 10, 48
- Martin G., 1997, J. Biol. Chem., 272, 28217
- Hofmann C., 1994, Endocrinology, 134, 270, 10.1210/endo.134.1.8275942 · DOI · Paper page
- Tai T.-A. C., 1996, J. Biol. Chem., 271, 29914
- Kelly L. J., 1998, Endocrinology, 139, 4927
- Hulin B., 1996, Curr. Pharm. Des., 2, 102
- Kletzien R. F., 1992, Mol. Pharmacol., 41, 398
- Ibrahimi A., 1994, Mol. Pharmacol., 46, 1076
- Harris P. K. W., 1994, Mol. Pharmacol., 45, 445
- Willson T. M., 1996, J. Med. Chem., 39, 668
- Ide T., 1998, Diabetes Front, 9, 346
- Shinkai H., 1998, J. Med. Chem., 41, 1933
- Reginato M. J., 1998, J. Biol. Chem., 273, 32684
- Reddy K. A., 1999, J. Med. Chem., 42, 3278
- Sohda T., 1984, Chem. Pharm. Bull., 32, 4465
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2126
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2130
- Henke B. R., 1998, Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem
- Collins J. L., 1998, Structure−activity relationship and optimization of the phenyl alkyl ether moiety. J. Med. Chem
- Cobb J. E., 1998, N-(2-Benzoylphenyl)-l-tyrosine PPARγ agonists. 3. Structure−activity relationship and optimization of the N-aryl substituent. J. Med. Chem., 41, 5069
- Lehmann J. M., 1997, J. Biol. Chem., 272, 3410
- Verrando P., 1981, Biochim. Biophys. Acta, 663, 265
- Negishi M., 1995, J. Lipid Mediators Cell Signalling, 12, 448
- Narumiya S., 1991, Dev. Oncol., 67, 448
- Ikeda H., 1990, Arzneim.-Forsch., 40, 162
- Horikoshi H., 1994, Annu. Rep. Sankyo Res. Lab., 46, 57
- Prigeon R. L., 1998, J. Clin. Endocrinol. Metab., 83, 823
- Fonseca V. A., 1998, J. Clin. Endocrinol. Metab., 83, 3176
- Spencer C. M., 1997, Drugs, 54, 101
- Kumar S., 1996, Diabetologia, 39, 709
- Gimble J. M., 1996, Mol. Pharmacol., 50, 1094
- Jones S. A., 2000, Mol. Endocrinol., 14, 39, 10.1210/mend.14.1.0409 · doi:10.1210/mend.14.1.0409 · Paper page
- Blumberg B., 1998, Genes Dev., 12, 3205
- Ramachandran V., 1999, Drug Metab. Dispos., 27, 1199
- Yamazaki H., 1999, Drug Metab. Dispos., 27, 1266
- Pumford N. R., 1997, Annu. Rev. Pharmacol. Toxicol., 37, 117
- Miller V. A., 1997, J. Clin. Oncol., 15, 795
- Rizvi N. A., 1999, Clin. Cancer Res., 5, 1664
- Vidal-Puig A. J., 1997, J. Clin. Invest., 99, 2422
- Park K. S., 1997, Diabetes, 46, 1234
- Wu Z., 1998, J. Clin. Invest., 101, 32
- Sreenan S., 1999, Am. J. Physiol., 276, E1129
- Miles P. D. G., 1997, Diabetes, 46, 1683
- Yen C.-J., 1997, Biochem. Biophys. Res. Commun., 241, 274
- Deeb S. S., 1998, Nat. Genet., 20, 287
- Valve R., 1999, J. Clin. Endocrinol. Metab., 84, 3712
- Mori Y., 1998, Biochem. Biophys. Res. Commun., 251, 198
- Ek J., 1999, Diabetologia, 42, 895
- Hamann A., 1999, Eur. J. Endocrinol., 141, 92
- Girard J, 1997, Diabetes Metab., 23, 24
- McKeigue P., 1997, Handb. Hypertens., 17, 934
- Dubey R. K., 1993, Am. J. Physiol., 265, R732
- Zhang H. Y., 1994, Hypertension, 24, 110
- Morikang E., 1997, Am. J. Hypertens., 10, 446
- Law R. E., 1996, J. Clin. Invest., 98, 1905
- Kotchen T. A., 1996, Am. J. Physiol., 270, R666
- Zhang F., 1994, Hypertension, 24, 175
- Su C. G., 1999, J. Clin. Invest., 104, 389
- Ehrmann D. A., 1997, J. Clin. Endocrinol. Metab., 82, 2116
- Minamikawa J., 1998, J. Clin. Endocrinol. Metab., 83, 1820
- Suh N., 1999, Cancer Res., 59, 5673
- Lefebvre A.-M., 1998, Nat. Med., 4, 1057
- Schmidt A., 1992, Mol. Endocrinol., 6, 1641
- Amri E.-Z., 1995, J. Biol. Chem., 270, 2371
- Brooks C. D. W., 1996, J. Med. Chem., 39, 2654
- Brun R. P., 1996, Genes Dev., 10, 984
- Lim H., 1999, Genes Dev., 13, 1574
- He T.-C., 1999, Cell, 99, 345
- Cobb J., 1998, Annu. Rep. Med. Chem., 33, 222
- Sliskovic D. R., 1999, Annu. Rep. Med. Chem., 34, 110
- Belch J. J. F., 1998, Proc. Nutr. Soc., 57, 569
- Woutersen R. A., 1999, Mutat. Res., 443, 127
Cited by
Items 501–600 of 1,003
Anti-obesity Effect of Pinellia ternata Extract in Zucker Rats
Kim, Y.-J., Shin, Y., Ha, Y.-W., Lee, S., Oh, J., & Kim, Y. S. (2006) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.29.1278 · Cited by 72
Oxidation-Sensitive Transcription Factors and Molecular Mechanisms in the Arterial Wall
de Nigris, F., Lerman, L. O., Condorelli, M., Lerman, A., & Napoli, C. (2001) · Antioxidants and Redox Signaling · doi:10.1089/152308601317203620 · Cited by 75
“Peroxisomes in liver parenchymal cells proliferate in response to structurally diverse nonmutagenic compounds designated as peroxisome proliferators (PP) (51, 55, 76).”
InfluentialRapid pain modulation with nuclear receptor ligands
Fehrenbacher, J. C., LoVerme, J., Clarke, W. P., Hargreaves, K., Piomelli, D., & Taylor, B. K. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.019 · Cited by 70
2-Phenethylamines in Medicinal Chemistry: A Review
Nieto, C. T., Manchado, A., Belda, L., David Diez, A., & Garrido, N. M. (2023) · Molecules · doi:10.3390/molecules28020855 · Cited by 66
Guo, C., Zhang, Y., He, L., Wang, F., Chen, K., Li, J., Li, S., Liu, T., Zheng, Y., Wang, J., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s79837 · Cited by 54
“The activity of fenofibrate toward the PPAR is strong when compared with that of bezafibrate.(26) Although many observational studies have been published, the mechanism by which fibrates reduce biochemical markers of cholestasis, and whether fibrate therapy improves survival in patients with these disorders, remain un…”
Batista, F. A. H., Trivella, D. B. B., Bernardes, A., Gratieri, J., Oliveira, P. S. L., Figueira, A. C. M., Webb, P., & Polikarpov, I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033643 · Cited by 61
“The pan-PPAR agonist benzafibrate [23]; activated PPARa, PPARd and PPARc with descending efficacy (Fig.”
BackgroundWei, Z.-L., & Kozikowski, A. P. (2003) · The Journal of Organic Chemistry · doi:10.1021/jo035140g · Cited by 64
de los Reyes, C., Ávila-Román, J., Ortega, M. J., de la Jara, A., García-Mauriño, S., Motilva, V., & Zubía, E. (2014) · Phytochemistry · doi:10.1016/j.phytochem.2014.03.011 · Cited by 63
Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet
Fernandes‐Santos, C., Carneiro, R. E., Mendonça, L. D. S., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2009) · Nutrition · doi:10.1016/j.nut.2008.12.010 · Cited by 72
Yu, C., Chen, L., Luo, H., Chen, J., Cheng, F., Gui, C., Zhang, R., Shen, J., Chen, K., Jiang, H., et al. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03937.x · Cited by 67
“The peroxisome proliferator-activated receptor (PPAR) belongs to the nuclear receptor superfamily [1] that plays an important role in the regulation of the storage and catabolism of dietary fats [2].”
BackgroundPPAR-γ inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1
Benkirane, K., Amiri, F., Diep, Q. N., Mabrouk, M. E., & Schiffrin, E. L. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00662.2005 · Cited by 70
High-throughput chemistry and structure-based design: survival of the smartest
Bailey, D. S., & Brown, D. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(00)01596-8 · Cited by 64
Patel, J. J., Butters, O., & Arnett, T. R. (2014) · Cell Biochemistry and Function · doi:10.1002/cbf.3025 · Cited by 67
“The stimulatory effect of fenofibrate on adipogenesis is consistent with previous pharmacological data showing that fenofibrate can bind to PPAR-α and PPAR-γ (with EC50 values in murine cell-based models of 18 and 250μM, respectively).(48) Thus, fenofibrate should be considered a selective rather than specific agonist…”
BackgroundInfluentialRamakers, J. D., Mensink, R. P., Schaart, G., & Plat, J. (2007) · Lipids · doi:10.1007/s11745-007-3071-3 · Cited by 68
“Troglitazone and GW7647 were used at a concentration where they are selective for their receptor subtypes [37, 38].”
BackgroundBattaglia, S., Maguire, O., Thorne, J. L., Hornung, L. B., Doig, C. L., Liu, S., Sucheston, L. E., Bianchi, A., Khanim, F. L., Gommersall, L. M., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq086 · Cited by 66
Sekulic‐Jablanovic, M., Petkovic, V., Wright, M. B., Kucharava, K., Huerzeler, N., Levano, S., Brand, Y., Leitmeyer, K., Glutz, A., Bausch, A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188596 · Cited by 64
Naim, M. J., Alam, O., Alam, M. J., Shaquiquzzaman, M., Alam, M. M., & Naidu, V. G. M. (2018) · Archiv der Pharmazie · doi:10.1002/ardp.201700223 · Cited by 63
Gizard, F., Nomiyama, T., Zhao, Y., Findeisen, H. M., Heywood, E. B., Jones, K. L., Staels, B., & Bruemmer, D. (2008) · Circulation Research · doi:10.1161/circresaha.108.186205 · Cited by 62
Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
P. Menendez-Gutierrez, M., Roszer, T., & Ricote, M. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436669 · Cited by 62
“Although each PPAR isotype is encoded by a separate gene, they share a high degree of amino acid sequence homology, resulting in some degree of cross reactivity [5].”
BackgroundNutrigenomics and Nutrigenetics of ω3 Polyunsaturated Fatty Acids
Heuvel, J. P. V. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-398397-8.00004-6 · Cited by 81
Hidalgo‐Figueroa, S., Ramírez‐Espinosa, J. J., Estrada-Soto, S. E., Almanza-Pérez, J. C., Román‐Ramos, R., Alarcón-Aguilar, F. J., Hernández‐Rosado, J. V., Moreno‐Díaz, H., Díaz-Coutiño, D., & Navarrete‐Vázquez, G. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12102 · Cited by 62
“4′-({4-[(2,4,6-trioxotetrahydropyrimidin-5(2H)ylidene)methyl]phenoxy}methyl)biphenyl-2carbonitrile (2) Yield: 73%, mp: 267 °C (dec).”
BackgroundBorland, M. G., Foreman, J. E., Girroir, E. E., Zolfaghari, R., Sharma, A. K., Amin, S., Gonzalez, F. J., Ross, A. C., & Peters, J. M. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.050609 · Cited by 60
“For example, PPAR is the molecular target for the fibrate class of hypolipidemic drugs (Peters et al., 2005), and PPAR is the molecular target of the thiazolidinedione class of insulin-sensitizing drugs (Willson et al., 2000).”
Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases
Khuchua, Z. A., Glukhov, A. I., Strauss, A. W., & Javadov, S. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113464 · Cited by 65
“The EC50s for BF are 50, 60, and 20 μM for human PPARα, PPARγ, and PPARβ/δ, respectively; and 90, 55, and 110 μM for mouse PPARα, PPARγ, and PPARβ/δ, respectively [18].”
BackgroundDegenhardt, T., Matilainen, M., Herzig, K.-H., Dunlop, T. W., & Carlberg, C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605623200 · Cited by 62
Fu, M., Zhang, J., Lin, Y. G., Zhu, X., Willson, T. M., & Chen, Y. E. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00533-8 · Cited by 66
Self-citationPershadsingh, H. A. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.08.006 · Cited by 69
Liu, W., Lau, F. W., Liu, K., Wood, H. B., Zhou, G., Chen, Y., Li, Y., Akiyama, T. E., Castriota, G. A., Einstein, M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201061j · Cited by 67
THIAZOLIDINE-2,4-DIONES: AN UPDATE REVIEW OF ANTIDIABETIC AGENTS
Dumbare, M., Kawale, L. A., Nade, V. S., & Deshmukh, R. (2018) · International Research Journal of Pharmacy · doi:10.7897/2230-8407.0812245 · Cited by 61
Gani, O. A. B. S. M., & Sylte, I. (2008) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2008.04.008 · Cited by 67
“Although the balance between PPARa and PPARg affinities is important in the design of effective dual agonists [4], binding affinities of DHA and its derivatives for PPARs are not available.”
BackgroundXu, Y., Mayhugh, D., Saeed, A., Wang, X., Thompson, R. C., Dominianni, S. J., Kauffman, R. F., Singh, J., Bean, J. S., Bensch, W. R., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034173l · Cited by 61
Fernandes-Santos, C., Evangelista Carneiro, R., de Souza Mendonca, L., Barbosa Águila, M., & Alberto Mandarim-de-Lacerda, C. (2009) · Pancreas · doi:10.1097/mpa.0b013e3181987d9d · Cited by 60
“The 3 PPAR isoforms (PPAR->, PPAR-A/C, and PPAR-F) are expressed in different tissues, each having various functions in lipoprotein metabolism and glucose homeostasis.(8,9) In the treatment of hyperlipidemia and type 2 diabetes, the significance of PPAR pathways in the management of metabolic disease is highlighted by…”
BackgroundGreene-Schloesser, D. M., Payne, V. S., Peiffer, A. M., Hsu, F., Riddle, D. R., Zhao, W., Chan, M. D., Metheny‐Barlow, L. J., & Robbins, M. E. C. (2014) · Radiation Research · doi:10.1667/rr13202.1 · Cited by 60
“The peroxisomal proliferator-activated receptor a (PPARa) is a nuclear receptor belonging to the PPAR family of ligand-activated transcription factors (16).”
Still, K., Grabowski, P., Mackie, I. P., Perry, M., & Bishop, N. J. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9175-9 · Cited by 60
“Still (&) P. Grabowski I. Mackie N. Bishop Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield S10 2TH, UK e-mail: k.still@sheffield.ac.uk; k.still@shef.ac.uk M. Perry Department of Anatomy, University of Bristol, Bristol, UK The PPARs are promiscuous receptors, and few spec…”
BackgroundInfluentialIalenti, A., Grassia, G., Meglio, P. D., Maffia, P., Rosa, M. D., & Ianaro, A. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.004895 · Cited by 68
“Their effects are exerted by binding to the intracellular glucocorticoid receptor (GR), which belongs, as does PPAR- , to the nuclear receptor gene family (Willson et al., 2000).”
BackgroundPeroxisome Proliferator-Activated Receptor γ-Mediated NF-κB Activation and Apoptosis in Pre-B Cells
Schlezinger, J. J., Jensen, B. A., Mann, K. K., Ryu, H., & Sherr, D. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.12.6831 · Cited by 63
“Synthetic ligands for PPAR include thiazolidinediones and tyrosine analogs, developed for the treatment of type II diabetes and investigated as chemotherapeutics (23), as well as a metabolite of di[2-ethylhexyl]phthalate, a major environmental pollutant (24).”
BackgroundInfluentialstgren, C. J., Lindblad, U., Melander, O., Melander, A., Groop, L., & stam, L. R. (2003) · Journal of Hypertension · doi:10.1097/00004872-200309000-00014 · Cited by 60
Brand, C. L., Sturis, J., Gotfredsen, C. F., Fleckner, J., Fledelius, C., Hansen, B. F., Andersen, B., Ye, J., Sauerberg, P., & Wassermann, K. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00348.2002 · Cited by 62
Guasch, L., Sala, E., Castell‐Auví, A., Cedó, L., Liedl, K. R., Wolber, G., Muehlbacher, M., Mulero, M., Pinent, M., Ardèvol, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050816 · Cited by 62
“Agonists of PPARa and PPARc are currently approved for treating dyslipidemia and type 2 diabetes, respectively [4,5].”
BackgroundEffect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats
Li, L., Li, L., Chen, L., Lin, X., Xu, Y., Ren, J., Fu, J., & Qiu, Y. (2014) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2014.12.001 · Cited by 62
Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents
Doshi, L. S., Brahma, M. K., Bahirat, U. A., Dixit, A. V., & Nemmani, K. V. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003640169 · Cited by 59
“PPARg , the receptor on which extensive research is in progress, has two isoforms: PPARg1, which is expressed in liver, skeletal muscle, cardiac muscle, kidney, intestines, spleen and white adipose tissue, while PPARg2 is expressed in white and brown adipose tissue [6].”
BackgroundFenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review
Τζιόμαλος, Κ., & Athyros, V. G. (2006) · International Journal of Nanomedicine · doi:10.2147/nano.2006.1.2.129 · Cited by 62
“We will also analyze the major trial that evaluated fibrates for primary and secondary prevention of CVD, the safety and efficacy profile of fibrate–statin combination treatment and the current recommendations regarding the use of fibrates in clinical practice.”
Bhagavathula, N., Nerusu, K. C., Lal, A., Ellis, C. N., Chittiboyina, A. G., Avery, M. A., Ho, C. I., Benson, S. C., Pershadsingh, H. A., Kurtz, T. W., et al. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2003.22111.x · Cited by 61
“The EC 50 value of pioglitazone for PPAR-γ activation has previously been reported to be in the range of 550 nM”
MethodCoordinate Regulation of Hepatic Bile Acid Oxidation and Conjugation by Nuclear Receptors
Trottier, J., Milkiewicz, P., Kaeding, J., Verreault, M., & Barbier, O. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060020t · Cited by 58
Benkirane, K., Viel, É. C., Amiri, F., & Schiffrin, E. L. (2005) · Hypertension · doi:10.1161/01.hyp.0000196728.05488.c3 · Cited by 64
PPARγ: observations in the hematopoietic system☆
Greene, M. E., Pitts, J. M., McCarville, M. B., Wang, X.-S., Newport, J. A., Edelstein, C. L., Lee, F., Ghosh, S., & Chu, S. (2000) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(00)00075-7 · Cited by 61
Tous, M., Ferré, N., Rull, A., Marsillach, J., Coll, B., Alonso‐Villaverde, C., Camps, J., & Joven, J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.109 · Cited by 66
Cerquetti, L., Sampaoli, C., Amendola, D., Bucci, B., Masuelli, L., Marchese, R., Misiti, S., Venanzi, A. D., Poggi, M., Toscano, V., et al. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.02.014 · Cited by 59
Wei, J., Bhattacharyya, S., Jain, M., & Varga, J. (2012) · The Open Rheumatology Journal · doi:10.2174/1874312901206010103 · Cited by 67
“Putative endogenous ligands include prostanoids such as 15-deoxy- 12,14-prostaglandin J2 (15d-PGJ2) and arachidonic acid derivatives synthesized through the lipoxygenase pathway such as 15-hydroxy-eicosatetraenoic acid (15-HETE) [55].”
BackgroundPPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home
Billin, A. N. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1465 · Cited by 57
“The L-165041 compound is not very potent on the murine PPARβ / δ receptor [10] , and subsequently the potent and selective non-TZD PPARβ / δ agonist GW501516 was evaluated and published by Glaxo Wellcome [11] .”
BackgroundMuralikumar, S., Vetrivel, U., Narayanasamy, A., & N. Das, U. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-016-0404-3 · Cited by 56
“Though the three isoforms of PPAR (α, β and γ) share high level of sequence and structural similarity they are distinct in terms of expression and tissue distribution [3].”
BackgroundParadis, A.-M., Fontaine‐Bisson, B., Bossé, Y., Robitaille, J., Lemieux, S., Jacques, H., Lamarche, B., Tchernof, A., Couture, P., & Vohl, M. (2005) · American Journal of Clinical Nutrition · doi:10.1093/ajcn.81.2.523 · Cited by 65
PPARγ pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells
Li, M., 邓华, Jia-ming, Z., Dai, D., & Tan, X.-Y. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i6.1220 · Cited by 58
5-Aryl thiazolidine-2,4-diones: discovery of PPAR dual α/γ agonists as antidiabetic agents
Desai, R. C., Han, W., Metzger, E. J., Bergman, J. P., Gratale, D. F., MacNaul, K. L., Berger, J. P., Doebber, T. W., Leung, K., Moller, D. E., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00505-5 · Cited by 58
Peroxisome proliferator-activated receptors in endothelial cell biology
Plutzky, J. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200110000-00006 · Cited by 60
Chikahisa, S., Tominaga, K., Kawai, T., Kitaoka, K., Oishi, K., Ishida, N., Rokutan, K., & Séi, H. (2008) · Endocrinology · doi:10.1210/en.2008-0285 · Cited by 57
Ghonem, N. S., Auclair, A. M., Hemme, C. L., Gallucci, G. M., de la Rosa Rodriguez, R., Boyer, J. L., & Assis, D. N. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1930 · Cited by 57
“Fibrates are synthetic PPAR ligands, which have been approved for the treatment of dyslipidemia,(18) although each fibrate differs in its specificity for the PPAR isoforms (α, δ/β, and γ).(19) The PPARα isoform transcriptionally activates gene expression of many bile acid metabolizing enzymes, including CYP7A1, CYP27A…”
BackgroundMolecular mechanisms of morphine tolerance and dependence; novel insights and future perspectives
Badshah, I., Anwar, M., Murtaza, B., & Khan, M. I. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04810-3 · Cited by 62
Zapata-Gonzalez, F., Rueda, F., Pétriz, J., Domingo, P., Villarroya, F., de Madariaga, M. A., & Domingo, J. C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6130 · Cited by 64
“Recently expression of PPAR in the immune system has been reported where it fulfils different roles as apoptotic cell inducer following T lymphocyte activation (25–27), antiproliferative effects on B lymphocytes (28), inhibition of cytokine production in monocytes and macrophages (29, 30), and regulation of DC immunog…”
BackgroundIdentification and regulation of novel PPAR-γ splice variants in human THP-1 macrophages
Chen, Y., Jimenez, A. R., & Medh, J. D. (2006) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/j.bbaexp.2006.01.005 · Cited by 71
“All PPAR subtypes form a heterodimer with the 9-cis-retinoic acid receptor (RXR) [3,4].”
BackgroundGani, O. A. B. S. M. (2008) · Cardiovascular Diabetology · doi:10.1186/1475-2840-7-6 · Cited by 61
Khan, O. A., Riazi, S., Hu, X., Song, J., Wade, J. B., & ECELBARGER, C. A. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00335.2004 · Cited by 59
Koyama, H., Miller, D. J., Boueres, J. K., Desai, R. C., Jones, A. B., Berger, J. P., MacNaul, K. L., Kelly, L. J., Doebber, T. W., Wu, M. S., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030621d · Cited by 61
Rudolph, J., Chen, L., Majumdar, D., Bullock, W. H., Burns, M. G., Claus, T. H., Cruz, F. E. D., Daly, M., Ehrgott, F. J., Johnson, J. S., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061299k · Cited by 60
Effects of Radiation Therapy on Neural Stem Cells
Michaelidesova, A. J., Konířová, J., Bartůněk, P., & Zíková, M. (2019) · Genes · doi:10.3390/genes10090640 · Cited by 60
Zhou, J., Wilson, K. M., & Medh, J. D. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00138-9 · Cited by 69
“PPAR-γ is the most extensively studied of the three PPAR subtypes and is a key regulator of adipocyte differentiation and carbohydrate metabolism [3].”
BackgroundLamotte, Y., Martres, P., Faucher, N., Laroze, A., Grillot, D., Ancellin, N., Saintillan, Y., Bénéton, V., & Gampe, R. T. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.12.107 · Cited by 56
Reevaluation of the PPAR-β/δ Ligand Binding Domain Model Reveals Why It Exhibits the Activated Form
Fyffe, S. A., Alphey, M. S., Buetow, L., Smith, T., Ferguson, M. A. J., Sørensen, M. D., Björkling, F., & Hunter, W. N. (2006) · Molecular Cell · doi:10.1016/j.molcel.2005.12.001 · Cited by 56
Liu, Y., Guo, G., Zheng, L., Sun, R., Wang, X., Deng, J., Jia, G., Yang, C., Cui, L., Guo, C., et al. (2023) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002238 · Cited by 55
“The PPAR-a isoform transcriptionally activates gene expression of many bile acid – metabolizing enzymes (31).”
BackgroundThe Role of PPARs in Breast Cancer
Zhao, B., Xin, Z., Ren, P., & Wu, H. (2022) · Cells · doi:10.3390/cells12010130 · Cited by 60
“The GW7647 is an excellent PPARα-specific agonist that could be used in experimental research since it is a powder with a melting point of 153–154 ◦C [28].”
BackgroundBurris, T. P., de Vera, I. M. S., Côté, I., Flaveny, C. A., Wanninayake, U. S., Chatterjee, A., Walker, J. K., Steinauer, N., Zhang, J., Coons, L. A., et al. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000436 · Cited by 56
Neher, M. D., Weckbach, S., Huber-Lang, M. S., & Stahel, P. F. (2012) · PPAR Research · doi:10.1155/2012/728461 · Cited by 55
“To date, three subtypes of PPARs have been identified in various species, PPARα, PPARβ/δ, and PPARγ, that exhibit differential tissue distributions and ligand specificities [9, 10].”
BackgroundJiménez, R., Sánchez, M., Zarzuelo-Romero, M. J., Romero, M., Quintela, A. M., López-Sepúlveda, R., Galindo, P., Gómez‐Guzmán, M., Haro, J. M., Zarzuelo, A., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.159806 · Cited by 66
“Because of the promising therapeutic role of PPAR- agonists and the relative lack of knowledge of the actions of PPAR- in the vascular territory, in this study we investigated the short-term effects of L-165041, a weak nonselective PPAR- agonist (Willson et al., 2000), and GW0742, a selective PPAR- agonist (Kim et al.”
BackgroundWu, L., Wang, R., deChamplain, J., & Tw, W. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.04.010 · Cited by 57
Chittiboyina, A. G., Venkatraman, M. S., Mizuno, C. S., Desai, P. V., Patny, A., Benson, S. C., Ho, C. I., Kurtz, T. W., Pershadsingh, H. A., & Avery, M. A. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0510880 · Cited by 55
Rangwala, S. M., & Lazar, M. A. (2002) · Science Signaling · doi:10.1126/stke.2002.121.pe9 · Cited by 57
Peroxisome Proliferator-activated Receptor γ-mediated Differentiation
Gupta, R. A., Sarraf, P., Mueller, E., Brockman, J. A., Prusakiewicz, J. J., Eng, C., Willson, T. M., & DuBois, R. N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300637200 · Cited by 59
Self-citationSynthesis and antihyperglycemic activity profiles of novel thiazolidinedione derivatives
Bhat, B. A., Ponnala, S., Sahu, D. P., Tiwari, P., Tripathi, B. K., & Srivastava, A. K. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.08.031 · Cited by 54
Rival, Y., Stennevin, A., Puech, L., Rouquette, A., Cathala, C., Lestienne, F., Dupont-Passelaigue, E., Patoiseau, J., Wurch, T., & Junquero, D. C. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068254 · Cited by 58
“0744 and fenofibric acid (almost inactive), in accordance with previous results (Lehmann et al., 1997; Oberfield et al., 1999; Willson et al., 2000; Adamson et al., 2002).”
ResultPeroxisome proliferator‐activated receptors (PPARs) in the control of bone metabolism
Giaginis, C., Tsantili‐Kakoulidou, A., & Theocharis, S. E. (2007) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2007.00486.x · Cited by 59
Nuclear receptor superfamily: Principles of signaling
Germain, P., Altucci, L., Bourguet, W., Rochette-Egly, C., & Gronemeyer, H. (2003) · Pure and Applied Chemistry · doi:10.1351/pac200375111619 · Cited by 53
“[42,43,59,60]).”
Bouhlel, M. A., Brozek, J., Derudas, B., Zawadzki, C., Jude, B., Staels, B., & Chinetti, G. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.06.047 · Cited by 53
Role of PPARs in Radiation-Induced Brain Injury
Ramanan, S., Zhao, W., Riddle, D. R., & Robbins, M. E. C. (2009) · PPAR Research · doi:10.1155/2010/234975 · Cited by 55
“Variation in the sequence of amino acids that line the ligandbinding pocket is a major determinant of ligand isotype specificity [7, 8].”
BackgroundA Live Zebrafish-Based Screening System for Human Nuclear Receptor Ligand and Cofactor Discovery
Tiefenbach, J., Moll, P. R., Nelson, M. R., Hu, C., Baev, L., Kislinger, T., & Krause, H. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009797 · Cited by 56
“However, as seen in Gal4-PPAR cell based assays [40], higher concentrations of the beta or alpha agonist do result in partial activation of the PPARc LT embryos (Figure S3a).”
BackgroundTutunchi, H., Ostadrahimi, A., Saghafi‐Asl, M., & Maleki, V. (2019) · Obesity Reviews · doi:10.1111/obr.12853 · Cited by 54
Peroxisome Proliferator-Activated Receptor Agonists Inhibit Inflammatory Edema and Hyperalgesia
Taylor, B. K., Dadia, N., Yang, C. B., Krishnan, S., & Badr, M. Z. (2002) · Inflammation · doi:10.1023/a:1015500531113 · Cited by 53
“As assessed by in vitro trans-activation studies ( 4 , 20) Taylor, Dadia, Yang, Krishnan, and Badr”
BackgroundMethodInfluentialCollino, M., Patel, N. S. A., Lawrence, K. M., Collin, M., Latchman, D. S., Yaqoob, M. M., & Thiemermann, C. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00430.x · Cited by 55
“10 , three isoforms—designated PPARα, PPARβsδ, and PPARγ—have been cloned and characterized by their distinct expression patterns, different ligand-binding specificity, and metabolic function”
BackgroundBinding of prostaglandins to human PPARγ: tool assessment and new natural ligands
Ferry, G., Bruneau, V., Beauverger, P., Goussard, M., Rodriguez, M., Lamamy, V., Dromaint, S., Canet, E., Galizzi, J., & Boutin, J. A. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00907-4 · Cited by 55
Gijsbers, L., Man, H.-Y., Kloet, S. K., de Haan, L. H. J., Keijer, J., Rietjens, I. M. C. M., van der Burg, B., & Aarts, J. M. M. J. G. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.02.032 · Cited by 60
“This ranking is in line with results found by Willson and coworkers [52], Lehmann and coworkers [62], Giaginis and coworkers [63], and Henke and coworkers [49], but it differs from the results found by Young”
BackgroundResultInfluentialTheocharis, S. E., Giaginis, C., Parasi, A. S., Margeli, A. P., Kakisis, J. D., Agapitos, E. B., & Kouraklis, G. P. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-9794-4 · Cited by 54
“PPAR-γ is expressed in various types of tissues and cells throughout the body [2, 4, 5].”
BackgroundInfluentialItoh, T., Murota, I., Yoshikai, K., Yamada, S., & Yamamoto, K. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.07.074 · Cited by 54
Scarsi, M., Podvinec, M., Roth, A. B., Hug, H., Kersten, S., Albrecht, H., Schwede, T. F., Meyer, U., & Rücker, C. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.024596 · Cited by 52
Rodriguez, M. A. D. L. R., Sugahara, G., Hooiveld, G. J. E. J., Ishida, Y., Tateno, C., & Kersten, S. (2018) · BMC Genomics · doi:10.1186/s12864-018-4834-3 · Cited by 54
Basic aspects of tumor cell fatty acid-regulated signaling and transcription factors
Comba, A., Lin, Y., Eynard, A. R., Valentich, M. A., Fernández-Zapico, M. E., & Pasqualini, M. E. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9308-x · Cited by 54
“The activation of transcription by the PPARs relies on two activation domains, i.e., activation function one (AF-1) located in the N-terminus and activation function two (AF2) located in the C-terminal LBD [44].”
BackgroundInfluentialEffectiveness of the PPARγ agonist, GW570, in liver fibrosis
Yang, L., Stimpson, S. A., Chen, L., Harrington, W. W., & Rockey, D. C. (2010) · Inflammation Research · doi:10.1007/s00011-010-0226-0 · Cited by 57
“GW570 is a potent PPARc ligand and agonist [15].”
Pinelli, A., Godio, C., Laghezza, A., Mitro, N., Fracchiolla, G., Tortorella, V., Lavecchia, A., Novellino, E., Fruchart, J., Staels, B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0502844 · Cited by 57
Liu, D., Zang, C., Liu, H., Possinger, K., Fan, S.-G., & Elstner, E. (2004) · PubMed · Cited by 52
The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome
Huang, T. H.-W., Teoh, A. W., Beilun, L., Lin, D. S.-H., & Roufogalis, B. D. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.03.020 · Cited by 54
Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b
Shipley, J. M., & Waxman, D. J. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2003.12.020 · Cited by 54
“…receptors (PPARs) are members of the nuclear receptor superfamily and are activated by a variety of natural and synthetic ligands (Willson et al., 2000), leading to the transcription of target genes involved in fatty acid metabolism (PPARa) (Schoonjans et 0041-008X/$ - see front…”
BackgroundMichellys, P. Y., Ardecky, R. J., Chen, J. H., Crombie, D. L., Etgen, G. J., Faulkner, A. L., Faul, M. M., Grese, T. A., Heyman, R. A., Karanewsky, D. S., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020340q · Cited by 51
Souza-Tavares, H., Miranda, C. S., Vasques‐Monteiro, I. M. L., Sandoval, C., Santana-Oliveira, D. A., Silva-Veiga, F. M., Fernandes‐da‐Silva, A., & Souza‐Mello, V. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i26.4136 · Cited by 54
Metadata
- Authors
- Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R.
- Affiliations
- Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-02-01
- Volume
- 43
- Issue
- 4
- Pages
- 527-550
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1977666051
- Cited by
- 1,816
- References
- 216
- Citations by year
- 2026: 18 · 2025: 28 · 2024: 27 · 2023: 35 · 2022: 38 · 2021: 41 · 2020: 38 · 2019: 44 · 2018: 46 · 2017: 44 · 2016: 37 · 2015: 60 · 2014: 62 · 2013: 52 · 2012: 92
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- peroxisome proliferator-activated receptors, orphan receptors, drug discovery, receptor agonists, ligands, lipid signaling, nuclear receptors
- MeSH terms
- Animals, Diabetes Mellitus, Humans, Hyperlipidemias, Hypertension, Inflammation, Ligands, Models, Molecular, Neoplasms, Nuclear Proteins, Obesity, Transcription Factors, Drug Design, Receptors, Cytoplasmic and Nuclear
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.